SM
ENSC icon

Sabby Management’s Ensysce Biosciences ENSC Stock Holding History

Sabby Management’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,954
Closed -$120K – 50
2025
Q1 		$120K Buy
+46,954
New +$272K 0.35% 34
2024
Q4 		– Sell
-77,506
Closed -$279K – 33
2024
Q3 		$279K Buy
77,506
+56,549
+270% +$343K 0.15% 16
2024
Q2 		$159K Buy
20,957
+5,587
+36% +$50.9K 0.11% 20
2024
Q1 		$182K Buy
+15,370
New +$244K 0.11% 25
2023
Q4 		– Sell
-6,465
Closed -$134K – 72
2023
Q3 		$134K Sell
6,465
-15,022
-70% -$426K 0.1% 43
2023
Q2 		$580K Buy
+21,487
New +$972K 0.47% 20

Other funds holding ENSC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management's ENSC Position: Q2 2025 in Review

Sabby Management sold out of Ensysce Biosciences (ENSC) in Q2 2025, closing a stake of 46,954 shares — an estimated $120K sold.

Sabby Management first reported a position in ENSC in Q2 2023 and held it in 6 quarters. The position peaked at $580K in Q2 2023. 11 funds tracked by Wall St. Rank hold ENSC as of Q2 2025.

  • Sabby Management reported no remaining Ensysce Biosciences position as of Q2 2025 after selling out during the quarter.
  • Sabby Management sold 46,954 Ensysce Biosciences shares in Q2 2025, an estimated $120K.
  • Sabby Management first reported a position in Ensysce Biosciences in Q2 2023 and held it in 6 quarters.
  • Sabby Management's Ensysce Biosciences position peaked at $580K in Q2 2023.
  • 11 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2025.

Based on Sabby Management's 13F filing for Q2 2025, filed 14 Aug 2025.